{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:36:27Z","timestamp":1791610587885,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human immunodeficiency virus-1 (HIV-1) infection remains to be one of the major threats throughout the world. Many researchers are working in this area to find a cure for HIV-1. The group of the FDA approved drugs which are currently used against HIV-1 in the clinical practice include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors (InIs), and protease inhibitors (PIs). Fixed dose combinations (FDCs) of these drugs are available and are used as per the anti-retroviral therapy (ART) guidelines. Despite these, unfortunately, there is no cure for HIV1 infection to date. The present review is focused upon describing the importance of a post-transcriptional regulatory protein \u201cRev\u201d, responsible for latent HIV-1 infection as a possible, and promising therapeutic target against HIV-1.<\/jats:p>","DOI":"10.1007\/s43440-021-00257-9","type":"journal-article","created":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:02:25Z","timestamp":1618099345000},"page":"1265-1272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein\u2014short review"],"prefix":"10.1007","volume":"73","author":[{"given":"Sahana","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Mudgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Venkatesh","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-9533","authenticated-orcid":false,"given":"K. Sreedhara Ranganath","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,11]]},"reference":[{"key":"257_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nm0703-853","volume":"9","author":"M Stevenson","year":"2003","unstructured":"Stevenson M. HIV-1 pathogenesis. Nat Med. 2003;9:853\u201360.","journal-title":"Nat Med"},{"key":"257_CR2","doi-asserted-by":"publisher","first-page":"574967","DOI":"10.1155\/2012\/574967","volume":"2012","author":"W Abbas","year":"2012","unstructured":"Abbas W, Herbein G. Molecular understanding of HIV-1 latency. Adv Virol. 2012;2012:574967.","journal-title":"Adv Virol"},{"key":"257_CR3","first-page":"13","volume":"3","author":"RM Hoetelmans","year":"1998","unstructured":"Hoetelmans RM. Sanctuary sites in HIV-1 infection. Antivir Ther. 1998;3:13\u20137.","journal-title":"Antivir Ther"},{"key":"257_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.immuni.2012.08.010","volume":"37","author":"E Eisele","year":"2012","unstructured":"Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37:377\u201388.","journal-title":"Immunity"},{"key":"257_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.biocel.2008.07.016","volume":"41","author":"H Zhang","year":"2009","unstructured":"Zhang H. Reversal of HIV-1 latency with anti-microRNA inhibitors. Int J Biochem Cell Biol. 2009;41:451\u20134.","journal-title":"Int J Biochem Cell Biol"},{"key":"257_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.biochem.67.1.1","volume":"67","author":"AD Frankel","year":"1998","unstructured":"Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem. 1998;67:1\u201325.","journal-title":"Annu Rev Biochem"},{"key":"257_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1089\/aid.2011.0230","volume":"28","author":"AA Waheed","year":"2012","unstructured":"Waheed AA, Freed EO. HIV type 1 Gag as a target for antiviral therapy. AIDS Res Hum Retrovir. 2012;28:54\u201375.","journal-title":"AIDS Res Hum Retrovir"},{"key":"257_CR8","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.3389\/fmicb.2018.02738","volume":"9","author":"S Lata","year":"2018","unstructured":"Lata S, Mishra R, Banerjea AC. Proteasomal degradation machinery: favorite target of HIV-1 proteins. Front Microbiol. 2018;9:2738.","journal-title":"Front Microbiol"},{"key":"257_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1006\/viro.1993.1605","volume":"197","author":"TM Niederman","year":"1993","unstructured":"Niederman TM, Hastings WR, Ratner L. Myristoylation-enhanced binding of the HIV-1 Net protein to T cell skeletal matrix. Virology. 1993;197:420\u20135.","journal-title":"Virology"},{"key":"257_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4690-5-84","volume":"5","author":"JL Foster","year":"2008","unstructured":"Foster JL, Garcia JV. HIV-1 Nef: at the crossroads. Retrovirology. 2008;5:1\u201313.","journal-title":"Retrovirology"},{"key":"257_CR11","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3389\/fimmu.2019.02151","volume":"10","author":"B Liu","year":"2019","unstructured":"Liu B, Zhang X, Zhang W, Wu L, Jing S, Liu W, et al. Lovastatin inhibits HIV-1-induced MHC-I downregulation by targeting Nef-AP-1 complex formation: a new strategy to boost immune eradication of HIV-1 infected cells. Front Immunol. 2019;10:2151.","journal-title":"Front Immunol"},{"key":"257_CR12","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1128\/jvi.63.9.3784-3791.1989","volume":"63","author":"K Strebel","year":"1989","unstructured":"Strebel K, Klimkait T, Maldarelli F, Martin MA. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol. 1989;63:3784\u201391.","journal-title":"J Virol"},{"key":"257_CR13","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.micinf.2008.07.006","volume":"10","author":"M Nomaguchi","year":"2008","unstructured":"Nomaguchi M, Fujita M, Adachi A. Role of HIV-1 Vpu protein for virus spread and pathogenesis. Microbes Infect. 2008;10:960\u20137.","journal-title":"Microbes Infect"},{"key":"257_CR14","doi-asserted-by":"publisher","first-page":"e1000869","DOI":"10.1371\/journal.ppat.1000869","volume":"6","author":"JG Magadan","year":"2010","unstructured":"Magadan JG, Perez-Victoria FJ, Sougrat R, Ye Y, Strebel K, Bonifacino JS. Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog. 2010;6:e1000869.","journal-title":"PLoS Pathog"},{"key":"257_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1126\/science.2981427","volume":"227","author":"J Sodroski","year":"1985","unstructured":"Sodroski J, Rosen C, Wong-Staal F, Salahuddin SZ, Popovic M, Arya S, et al. Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science. 1985;227:171\u20133.","journal-title":"Science"},{"key":"257_CR16","first-page":"80","volume":"30","author":"D Kamori","year":"2017","unstructured":"Kamori D, Ueno T. HIV-1 tat and viral latency: what we can learn from naturally occurring sequence variations. Front Microbiol. 2017;30:80.","journal-title":"Front Microbiol"},{"key":"257_CR17","first-page":"217","volume":"5","author":"A Gatignol","year":"1996","unstructured":"Gatignol A, Duarte M, Daviet L, Chang YN, Jeang KT. Sequential steps in tat Trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors. Gene Expr. 1996;5:217\u201328.","journal-title":"Gene Expr"},{"key":"257_CR18","doi-asserted-by":"publisher","first-page":"e12686","DOI":"10.7554\/eLife.12686","volume":"5","author":"M Barboric","year":"2016","unstructured":"Barboric M, Fujinaga KHIV. The two sides of Tat. Elife. 2016;5:e12686.","journal-title":"Elife"},{"key":"257_CR19","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1128\/jvi.64.6.3097-3099.1990","volume":"64","author":"EA Cohen","year":"1990","unstructured":"Cohen EA, Dehni G, Sodroski JG, Haseltine WA. Human-immunodeficiency-virus Vpr product is a virion-associated regulatory protein. J Virol. 1990;64:3097\u20139.","journal-title":"J Virol"},{"key":"257_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1742-4690-8-25","volume":"8","author":"M Kogan","year":"2011","unstructured":"Kogan M, Rappaport J. HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology. 2011;8:25.","journal-title":"Retrovirology"},{"key":"257_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nm0198-065","volume":"4","author":"WC Goh","year":"1998","unstructured":"Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med. 1998;4:65\u201371.","journal-title":"Nat Med"},{"key":"257_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1146\/annurev.micro.52.1.491","volume":"52","author":"VW Pollard","year":"1998","unstructured":"Pollard VW, Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol. 1998;52:491\u2013532.","journal-title":"Annu Rev Microbiol"},{"key":"257_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4161\/rna.9.1.18178","volume":"9","author":"JD Fernandes","year":"2012","unstructured":"Fernandes JD, Jayaraman B, Frankel AD. The HIV-1 Rev response element An RNA scaffold that directs the cooperative assembly of a homo-oligomeric ribonucleoprotein complex. RNA Biol. 2012;9:6\u201311.","journal-title":"RNA Biol"},{"key":"257_CR24","doi-asserted-by":"publisher","first-page":"e00545","DOI":"10.1128\/AAC.00545-17","volume":"61","author":"JM Steens","year":"2017","unstructured":"Steens JM, Scherrer D, Gineste P, Barrett PN, Khuanchai S, Winai R, et al. Safety, pharmacokinetics, and antiviral activity of a novel HIV antiviral, ABX464, in treatment-naive HIV-infected subjects in a phase 2 randomized, controlled study. Antimicrob Agents Chemother. 2017;61:e00545-e617.","journal-title":"Antimicrob Agents Chemother"},{"key":"257_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12977-015-0189-x","volume":"12","author":"B Berkhout","year":"2015","unstructured":"Berkhout B, van der Velden YU. ABX464: a good drug candidate instead of a magic bullet. Retrovirology. 2015;12:64.","journal-title":"Retrovirology"},{"key":"257_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12977-015-0159-3","volume":"12","author":"N Campos","year":"2015","unstructured":"Campos N, Myburgh R, Garcel A, Vautrin A, Lapasset L, Nadal ES, et al. Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis. Retrovirology. 2015;12:30.","journal-title":"Retrovirology"},{"key":"257_CR27","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157:1262\u201378.","journal-title":"Cell"},{"key":"257_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397\u2013405.","journal-title":"Trends Biotechnol"},{"key":"257_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.32607\/20758251-2014-6-3-19-40","volume":"6","author":"AA Nemudryi","year":"2014","unstructured":"Nemudryi AA, Valetdinova KR, Medvedev SP, Zakian SM. TALEN and CRISPR\/Cas genome editing systems: tools of discovery. Acta Nat. 2014;6:19\u201340.","journal-title":"Acta Nat"},{"key":"257_CR30","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nbt1353","volume":"25","author":"A Lombardo","year":"2007","unstructured":"Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol. 2007;25:1298\u2013306.","journal-title":"Nat Biotechnol"},{"key":"257_CR31","doi-asserted-by":"publisher","first-page":"7784","DOI":"10.1038\/s41598-018-26190-1","volume":"8","author":"Y Ophinni","year":"2018","unstructured":"Ophinni Y, Inoue M, Kotaki T, Kameoka M. CRISPR\/Cas9 system targeting regulatory genes of HIV-1 inhibits viral replication in infected T-cell cultures. Sci Rep. 2018;8:7784.","journal-title":"Sci Rep"},{"key":"257_CR32","doi-asserted-by":"publisher","first-page":"10437","DOI":"10.1073\/pnas.1512503112","volume":"112","author":"K Schumann","year":"2015","unstructured":"Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA. 2015;112:10437\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"257_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0378-1119(94)90409-X","volume":"149","author":"Z Chen","year":"1994","unstructured":"Chen Z, Bahner IC, Larson GP, Zaia JA, Rossi JJ, Kohn DB. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene. 1994;149:33\u20139.","journal-title":"Gene"},{"key":"257_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1089\/aid.1992.8.183","volume":"8","author":"JJ Rossi","year":"1992","unstructured":"Rossi JJ, Elkins D, Zaia JA, Sullivan S. Ribozymes as anti-Hiv-1 therapeutic agents - principles, applications, and problems. AIDS Res Hum Retrovir. 1992;8:183\u20139.","journal-title":"AIDS Res Hum Retrovir"},{"key":"257_CR35","doi-asserted-by":"publisher","first-page":"66ra6","DOI":"10.1126\/scitranslmed.3001581","volume":"3","author":"CP Neff","year":"2011","unstructured":"Neff CP, Zhou J, Remling L, Kuruvilla J, Zhang J, Li H, et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med. 2011;3:66ra6.","journal-title":"Sci Transl Med"},{"key":"257_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0169-409X(00)00085-5","volume":"44","author":"JJ Rossi","year":"2000","unstructured":"Rossi JJ. Ribozyme therapy for HIV infection. Adv Drug Deliv Rev. 2000;44:71\u20138.","journal-title":"Adv Drug Deliv Rev"},{"key":"257_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nm.1932","volume":"15","author":"RT Mitsuyasu","year":"2009","unstructured":"Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med. 2009;15:285\u201392.","journal-title":"Nat Med"},{"key":"257_CR38","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/sj.mt.6300157","volume":"15","author":"J Anderson","year":"2007","unstructured":"Anderson J, Li MJ, Palmer B, Remling L, Li S, Yam P, et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, Tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells. Mol Ther. 2007;15:1182\u20138.","journal-title":"Mol Ther"},{"key":"257_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S1525-0016(03)00140-0","volume":"8","author":"A Banerjea","year":"2003","unstructured":"Banerjea A, Li MJ, Bauer G, Remling L, Lee NS, Rossi J, et al. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther. 2003;8:62\u201371.","journal-title":"Mol Ther"},{"key":"257_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1742-4690-2-53","volume":"2","author":"J Anderson","year":"2005","unstructured":"Anderson J, Akkina R. CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology. 2005;2:53.","journal-title":"Retrovirology"},{"key":"257_CR41","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.4049\/jimmunol.169.9.5196","volume":"169","author":"J Capodici","year":"2002","unstructured":"Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol. 2002;169:5196\u2013201.","journal-title":"J Immunol"},{"key":"257_CR42","doi-asserted-by":"publisher","first-page":"e1003241","DOI":"10.1371\/journal.ppat.1003241","volume":"9","author":"RW Wong","year":"2013","unstructured":"Wong RW, Balachandran A, Ostrowski MA, Cochrane A. Digoxin suppresses HIV-1 replication by altering viral RNA processing. PLoS Pathog. 2013;9:e1003241.","journal-title":"PLoS Pathog"},{"key":"257_CR43","doi-asserted-by":"publisher","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","volume":"11","author":"OS Sogaard","year":"2015","unstructured":"Sogaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 2015;11:e1005142.","journal-title":"PLoS Pathog"},{"key":"257_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.virol.2011.10.024","volume":"422","author":"N Biswas","year":"2012","unstructured":"Biswas N, Wang TY, Ding M, Tumne A, Chen Y, Wang QD, et al. ADAR1 is a novel multi targeted anti-HIV-1 cellular protein. Virology. 2012;422:265\u201377.","journal-title":"Virology"},{"key":"257_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/095632029300400205","volume":"4","author":"H Schr\u00f6der","year":"1993","unstructured":"Schr\u00f6der H, Ushijima H, Bek A, Merz H, Pfeifer K, M\u00fcller W. Inhibition of formation of Rev-RRE complex by pyronin Y. Antivir Chem Chemother. 1993;4:103\u201311.","journal-title":"Antivir Chem Chemother"},{"key":"257_CR46","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/0092-8674(93)90720-B","volume":"74","author":"ML Zapp","year":"1993","unstructured":"Zapp ML, Stern S, Green MR. Small molecules that selectively block RNA-binding of Hiv-1 Rev protein inhibit rev function and viral production. Cell. 1993;74:969\u201378.","journal-title":"Cell"},{"key":"257_CR47","doi-asserted-by":"publisher","first-page":"e0211111","DOI":"10.1371\/journal.pone.0211111","volume":"14","author":"S Modai","year":"2019","unstructured":"Modai S, Farberov L, Herzig E, Isakov O, Hizi A, Shomron N. HIV-1 infection increases microRNAs that inhibit Dicer1, HRB and HIV-EP2, thereby reducing viral replication. PLoS ONE. 2019;14:e0211111.","journal-title":"PLoS ONE"},{"key":"257_CR48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bcp.2018.07.040","volume":"156","author":"S Prado","year":"2018","unstructured":"Prado S, Beltran M, Moreno A, Bedoya LM, Alcami J, Gallego J. A small-molecule inhibitor of HIV-1 Rev function detected by a diversity screen based on RRE-Rev interference. Biochem Pharmacol. 2018;156:68\u201377.","journal-title":"Biochem Pharmacol"},{"key":"257_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1074-5521(97)90257-X","volume":"4","author":"B Wolff","year":"1997","unstructured":"Wolff B, Sanglier JJ, Wang Y. Leptomycin B is an inhibitor of nuclear export: Inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol. 1997;4:139\u201347.","journal-title":"Chem Biol"},{"key":"257_CR50","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1089\/hum.1995.6.12-1561","volume":"6","author":"L Duan","year":"1995","unstructured":"Duan L, Zhu M, Bagasra O, Pomerantz RJ. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments. Hum Gene Ther. 1995;6:1561\u201373.","journal-title":"Hum Gene Ther"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00257-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-021-00257-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00257-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T06:45:40Z","timestamp":1632465940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-021-00257-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,11]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["257"],"URL":"https:\/\/doi.org\/10.1007\/s43440-021-00257-9","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,11]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}